Horizon Discovery Completes Acquisition of Hypoxium, Launches Horizon Discovery Services | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Horizon Discovery today announced it has completed its acquisition of contract research organization Hypoxium and formed a wholly owned subsidiary called Horizon Discovery Services.

HDS will provide oncology translational research services, such as drug profiling, novel 2D and 3D phenotypic assays, tumor microenvironment studies, and responsive-patient prediction. The services include access to Horizon's 250-plus patient relevant human isogenic cancer cell models.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.